دسترسی به 50 عنوان مجلات Science Direct

     پیرو توافق شورای تأمین منابع علمی و شرکت الزویر، بدینوسیله به آگاهی می‌رساند با توجه به مشکلات دانشگاه‌ها و قطع دسترسی به پایگاه ساینس دایرکت، پس از توافق بر سر اشتراک اسکوپوس، با این شرکت، مقرر شد 50 عنوان پرمصرف‌ترین مجلات سال 2019 دانشگاه‌های ایران را به‌صورت رایگان در دسترس پژوهشگران قرار دهند. بدینوسیله در زیر،  نامة شرکت و شیوه دسترسی به این عناوین را حضورتان تقدیم می‌نماید. این دسترسی تا 15 ژانویه 2022 برقرار خواهد بود.

Dear Customer,

We are pleased to provide you and your users with the information you need to successfully trial ScienceDirect at Ministry of Science Research and Technology of the Islamic Republic of Iran.

Your trial end date:  15 January 2022

This limited trial access provided to your organization is for product testing purposes only and will be subject to the terms set forth in the Elsevier terms and conditions, including but not limited to the usage restrictions and limitations of liability set forth therein. https://www.elsevier.com/legal/elsevier-website-terms-and-conditions

Getting Started:

Please check your trial access by going to the following URL; www.sciencedirect.com

Attached list of titles

Access is provided to you via:

Your access method: Access has been set up via existing access method. Please continue using the existing IP range (or) user names and passwords, Open Athens or Shibboleth authentication.

To access tools and resources to help you get the most out of ScienceDirect, please visit our Learn & Support page: http://www.elsevier.com/solutions/sciencedirect/support

Keep up to date:

Here are a few ways to learn the latest about ScienceDirect:

< >Subscribe to our ongoing ScienceDirect Newsletter here [Embed link: https://communications.elsevier.com/webApp/els_doubleOptInWA?do=0&srv=els_science_direct&sid=68&uif=0&uvis=3]Follow @sciencedirect on Twittersupport center overview page. Here you will find links to all our products online support, where you can contact us and find answers to frequently asked questions.

Please do not reply to this message as this is an automated email which cannot receive responses. Kindly contact us via our support center

Disclaimer: This email is for use by the intended recipient and contains information that may be confidential. If you are not the intended recipient, please notify the sender by return email and delete this email from your inbox. Any unauthorized use or distribution of this email, in whole or in part, is strictly prohibited and may be unlawful.